EDSA supply chain intelligence for Edesa Biotech, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Edesa Biotech, Inc. (EDSA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CMOS | CMOS | 92% | we are engaged in discussions with various CMOs regarding long-term supply agreements |
| PHARMACEUTICAL-DEVELOPMENT-COMPANY | PHARMACEUTICAL-DEVELOPMENT-COMPANY | 90% | In April 2020, the Company entered into a license agreement with a pharmaceutical development company to obtain exclusive world-wide rights to know-how, patents and data relating to certain monoclona… |
| THIRD-PARTY | THIRD-PARTY | 85% | In March 2021, through its Ontario subsidiary, the Company entered into a license agreement with the inventor of the same pharmaceutical product to acquire global rights for all fields of use beyond … |
| ACRS | Aclaris Therapeutics, Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| ACRS | Aclaris Therapeutics, Inc. | 72% | Reciprocal relationship from ACRS graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mo… |
| CMMB | Chemomab Therapeutics Ltd. | 72% | Reciprocal relationship from CMMB graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mo… |
| CMMB | Chemomab Therapeutics Ltd. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw mate… |
| LLY | Eli Lilly and Company | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| MESO | Mesoblast Limited | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| MESO | Mesoblast Limited | 72% | Reciprocal relationship from MESO graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from MESO graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw ma… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mor… |
| MRK | Merck & Co., Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mo… |
| VYNE | VYNE Therapeutics Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| VYNE | VYNE Therapeutics Inc. | 72% | Reciprocal relationship from VYNE graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mo… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PURCHASERS | PURCHASERS | 92% | The Purchasers have agreed to purchase, for an aggregate purchase price of approximately $3.5 million, an aggregate of 729,241 common shares |
| ACRS | Aclaris Therapeutics, Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| ACRS | Aclaris Therapeutics, Inc. | 72% | Reciprocal relationship from ACRS graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mo… |
| CM | Canadian Imperial Bank of Commerce | 72% | . The Warrants expire five years from the issuance date. In October 2023, the Company entered into a multi-year contribution agreement (2023 SIF Agreement) with the Canadian Government’s Strategic In… |
| CM | Canadian Imperial Bank of Commerce | 72% | Reciprocal relationship from CM graph: Reciprocal relationship from EDSA graph: . The Warrants expire five years from the issuance date. In October 2023, the Company entered into a multi-year contrib… |
| CMMB | Chemomab Therapeutics Ltd. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| CMMB | Chemomab Therapeutics Ltd. | 72% | Reciprocal relationship from CMMB graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from CMMB graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw ma… |
| LLY | Eli Lilly and Company | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mor… |
| MESO | Mesoblast Limited | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| MESO | Mesoblast Limited | 72% | Reciprocal relationship from MESO graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mo… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from MRK grap… |
| MRK | Merck & Co., Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw ma… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| VYNE | VYNE Therapeutics Inc. | 72% | ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for … |
| VYNE | VYNE Therapeutics Inc. | 72% | Reciprocal relationship from VYNE graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been mo… |
| PARDEEP-NIJHAWAN-MEDICINE-PROFESSIONAL-CORPORATI | PARDEEP-NIJHAWAN-MEDICINE-PROFESSIONAL-CORPORATI | 62% | . The Warrants expire five years from the issuance date. In October 2023, the Company entered into a multi-year contribution agreement (2023 SIF Agreement) with the Canadian Government’s Strategic In… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| EDSA-DEBT-60870 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| EDSA-DEBT-9232 | Warrants outstanding: 1122076 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| EDSA-OWNER-PERCEPTIVE-ADVISORS-LLC | PERCEPTIVE ADVISORS LLC | 90% | 13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 30 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ADAG | Adagene Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| ZTS | Zoetis Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| VEEV | Veeva Systems Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 |